Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
2.0100 x 10 2.1000 x 1
Post-market by (Cboe BZX)
2.0600 +0.1100 (+5.64%) 04/23/25 [NASDAQ]
2.0100 x 10 2.1000 x 1
Post-market 2.0799 +0.0199 (+0.97%) 16:46 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.9300
Day High
2.0950
Open 2.0200
Previous Close 1.9500 1.9500
Volume 729,100 729,100
Avg Vol 807,725 807,725
Stochastic %K 54.60% 54.60%
Weighted Alpha -73.99 -73.99
5-Day Change +0.3300 (+19.08%) +0.3300 (+19.08%)
52-Week Range 1.5300 - 13.4300 1.5300 - 13.4300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,265
  • Shares Outstanding, K 37,572
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,430 K
  • EBIT $ -144 M
  • EBITDA $ -142 M
  • 60-Month Beta -0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.21

Options Overview Details

View History
  • Implied Volatility 127.07% ( -52.66%)
  • Historical Volatility 108.13%
  • IV Percentile 62%
  • IV Rank 11.62%
  • IV High 747.02% on 04/14/25
  • IV Low 45.55% on 06/06/24
  • Put/Call Vol Ratio 6.83
  • Today's Volume 838
  • Volume Avg (30-Day) 324
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 9,684
  • Open Int (30-Day) 16,636

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.84
  • Number of Estimates 2
  • High Estimate -0.82
  • Low Estimate -0.85
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +22.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5300 +34.64%
on 04/09/25
Period Open: 2.8700
3.0800 -33.03%
on 03/24/25
-0.8100 (-28.22%)
since 03/21/25
3-Month
1.5300 +34.64%
on 04/09/25
Period Open: 4.4800
4.5900 -55.12%
on 01/24/25
-2.4200 (-54.02%)
since 01/23/25
52-Week
1.5300 +34.64%
on 04/09/25
Period Open: 10.9800
13.4300 -84.66%
on 05/16/24
-8.9200 (-81.24%)
since 04/23/24

Most Recent Stories

More News
IVEY PMI Reading Due Next Week in Canada

IVEY PMI Reading Due Next Week in Canada U.S. Monday Economic Lookahead Consumer credit ...

WDFC : 224.16 (-0.34%)
TLRY.TO : 0.61 (-4.69%)
JPM : 240.88 (+2.25%)
AGF-B.TO : 9.68 (+3.53%)
MAMA : 6.35 (+0.32%)
CCA.TO : 64.37 (-2.76%)
BYRN : 22.25 (+5.30%)
RPM : 103.80 (-0.21%)
DAL : 41.40 (+2.63%)
LEVI : 15.69 (+1.42%)
SMPL : 36.19 (-0.14%)
PLAY : 19.48 (-1.52%)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BMEA : 2.0600 (+5.64%)
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

BMEA : 2.0600 (+5.64%)
Biomea Fusion Announces Leadership Transition

BMEA : 2.0600 (+5.64%)
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

BMEA : 2.0600 (+5.64%)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BMEA : 2.0600 (+5.64%)
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

BMEA : 2.0600 (+5.64%)
Biomea Fusion to Become a Diabetes & Obesity Medicines Company

BMEA : 2.0600 (+5.64%)
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

BMEA : 2.0600 (+5.64%)
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BMEA : 2.0600 (+5.64%)

Business Summary

Biomea Fusion Inc. is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion Inc. is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 2.2900
2nd Resistance Point 2.1900
1st Resistance Point 2.1300
Last Price 2.0600
1st Support Level 1.9600
2nd Support Level 1.8600
3rd Support Level 1.8000

See More

52-Week High 13.4300
Fibonacci 61.8% 8.8800
Fibonacci 50% 7.4800
Fibonacci 38.2% 6.0800
Last Price 2.0600
52-Week Low 1.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective